GlaxoSmithKline plc vs AstraZeneca plc: Which Pharmaceutical Major Should You Add To Your ISA?

If you could only choose either GlaxoSmithKline plc (LON: GSK) or AstraZeneca plc (LON: AZN), which should it be?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the turn of the year, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has easily outperformed AstraZeneca (LSE: AZN) (NYSE: AZN.US), with the former’s share price rising by 14% compared to a gain of just 3% for the latter. Of course, this is only a three month period but, nevertheless, could it be the start of a sustained period of outperformance by GlaxoSmithKline? Or, is AstraZeneca a better buy than its sector peer?

Creating Value

Looking ahead, the two companies intend to create shareholder value in slightly different ways. In the case of AstraZeneca, it plans to continue the policy it has adopted in recent years of acquiring smaller entities in order to improve its long term pipeline potential. This is a sound strategy which should bode well for the long run, with AstraZeneca having only a moderate level of balance sheet gearing and very strong cash flow which will allow it to maintain a relatively high frequency of purchases.

In contrast, GlaxoSmithKline is planning on spinning off at least one subsidiary and also entering into agreements with other major pharmaceutical companies to jointly develop new products. For example, it entered into an agreement with Novartis to create a consumer healthcare business in which GlaxoSmithKline has a majority stake. This should allow it to spread capital and risk more effectively, which could prove to be a shrewd move in the long run.

Investor Sentiment

As mentioned, investor sentiment in GlaxoSmithKline has picked up in recent months, as the market begins to warm to the company’s growth and cost cutting strategy. Of course, an additional reason why GlaxoSmithKline’s shares have risen faster than those of AstraZeneca is the fact that it trades on a more appealing valuation to its sector peer. For example, GlaxoSmithKline has a price to earnings (P/E) ratio of 16.6, while AstraZeneca’s is slightly higher at 17.1. As such, there is greater scope for an upward rerating of GlaxoSmithKline’s shares moving forward.

Furthermore, GlaxoSmithKline has arguably had more challenging news flow to address than AstraZeneca in recent years. For example, it was embroiled in allegations of bribery for much of the last couple of years, which dampened investor sentiment at the same time as AstraZeneca enjoyed an uplift from bids and bid rumours. Moving forward, it could be the case that GlaxoSmithKline sees its share price move higher at a faster pace than AstraZeneca simply due to a new period that includes a lack of negative news flow surrounding its operations.

Looking Ahead

While both companies offer considerable future potential, GlaxoSmithKline continues to offer a greater breadth of appeal than AstraZeneca. For example, it has a lower valuation, a sound strategy and is likely to enjoy a period of improved news flow relative to its peer than it has done in recent years. As such, and while both companies are worth buying, GlaxoSmithKline seems to be the one to buy first at the present time.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »